Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because, numbers of tests shipped and $$ collected is usually 2-different things, especially when your dealing with governments.
Let’s go baby...
I’m out, I got in at $3.50, GLTA
Nice move here...
I’m glad I took profit on the pre market pump.... WHEW
I hopped off this crazy train, GLTA...
Is that float correct? 4.9 million?
I loaded .90 and sold 1.34... GLTA
He’s been bashing about all the corona plays.
Hmm to buy or not to buy... LOL
Show file list Print Zoom in Zoom out
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
April 27, 2020 (April 21, 2020)
AIM IMMUNOTECH INC.
(Exact name of registrant as specified in its charter)
Delaware 001 - 27072 52-0845822
(state or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
2117 SW Highway 484, Ocala FL 34473
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (352) 448-7797
AIM ImmunoTech Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share AIM NYSE American
Item 1.01 Entry into a Material Definitive Agreement.
On April 21, 2020, AIM entered into a Mutual Confidentiality Agreement with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. (collectively, the “Entities”) for the purpose of evaluation and discussion for certain business relationships concerning a COVID-19 therapeutic and vaccine. Current discussions with the Entities are preliminary and we anticipate that, if the parties determine to proceed, initial activity will consist of preclinical animal studies of Ampligen.
We have filed herewith as Exhibit 10.1, the Mutual Confidentiality Agreement, which is incorporated herein by reference, and the foregoing description of the Agreement is qualified in its entirety by reference thereto.
And he’s been busted for coke and arrested for fraud cause he falsely reported against another company , real stand up guy, LMMFAO...
Nope, he’ll of a run and close for a Friday with day traders and flippers moving to cash for the weekend.
I’m sure with gates and the government involved they have been vetted enough to not have any worry of a suspension.
Crazy volume, could see one hell of a SQUEEEEZE...
Well bro the market completely disagrees with you...
Well the FCC is fine with it. That’s makes it all good...
Huge news, should see new HOY
Good job and no doubt...
I took profit at 25, had to, Ive been here since 4, I’ll be back on the drop of there is one, if not good luck to you.
Market seems to like it...
Phase 3 NANO passed blockbuster drug potential, $50 easy with FDA approval...
Same back at ya...
YEAH BABY
Looks like the bulls showed up...
There will never be a lawsuit, I guarantee it... watch
They need some commitments, then it will fly again and everyone is nervous about dilution...
Agreed, I’m only nibbling with houses $$, profits from this morning...
Got some
I’m still waiting for reentry, hopefully 6.20’s
LOL, right...
No, I’ve been watching, he talking shit. If they do, I would expect AH.
Low floater, just keep on watch for offering...
I was lucky and got 4’s, so I’m still holding my core, I’m gonna hang in a little while longer, lots of news to come yet... GLTY
No doubt, could double again...
I loaded at $3.50 sold $8.50, I’m hoping for big dip from shorts... GLTY
Novavax to commence Phase 1 vaccine trial COVID-19 with Nucleus Network
As part of the urgent global race to develop a vaccine to tackle the Coronavirus COVID-19 outbreak, Nucleus is due to commence Phase 1 testing for the Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, at its Melbourne and Brisbane clinics within the coming weeks.
Novavax''s early development efforts on vaccines for two other recent coronavirus epidemics -- severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), along with prior work on Ebola (phase 1 trial conducted in Australia) -- allows them to leverage their understanding of coronaviruses and adapt their research to create a vaccine for SARS-CoV-2, the virus that causes COVID-19.
What’s the news
News out